Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.

Autor: Varga A; Gustave Roussy Cancer Center, Villejuif, France. Andrea.VARGA@gustaveroussy.fr., Soria JC; Gustave Roussy Cancer Center, Villejuif, France.; Universite Paris Sud, Orsay, France., Hollebecque A; Gustave Roussy Cancer Center, Villejuif, France., LoRusso P; Yale Cancer Center, New Haven, Connecticut., Bendell J; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Huang SA; Genentech, Inc., South San Francisco, California., Wagle MC; Genentech, Inc., South San Francisco, California., Okrah K; Genentech, Inc., South San Francisco, California., Liu L; Genentech, Inc., South San Francisco, California., Murray E; Genentech, Inc., South San Francisco, California., Sanabria-Bohorquez SM; Genentech, Inc., South San Francisco, California., Tagen M; Genentech, Inc., South San Francisco, California., Dokainish H; Genentech, Inc., South San Francisco, California., Mueller L; Genentech, Inc., South San Francisco, California., Burris H; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Mar 15; Vol. 26 (6), pp. 1229-1236. Date of Electronic Publication: 2019 Dec 17.

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.

Autor: Lamberts LE; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Menke-van der Houven van Oordt CW; Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands., ter Weele EJ; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Bensch F; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Smeenk MM; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Voortman J; Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands., Hoekstra OS; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands., Williams SP; Department of Early Clinical Development, Genentech, Inc. South San Francisco, California., Fine BM; Department of Biomedical Imaging, Genentech, Inc. South San Francisco, California., Maslyar D; Department of Biomedical Imaging, Genentech, Inc. South San Francisco, California., de Jong JR; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Gietema JA; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Schröder CP; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Bongaerts AH; Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Lub-de Hooge MN; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Verheul HM; Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands., Sanabria Bohorquez SM; Department of Biomedical Imaging, Genentech, Inc. South San Francisco, California., Glaudemans AW; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., de Vries EG; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. e.g.e.de.vries@umcg.nl.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Apr 01; Vol. 22 (7), pp. 1642-52. Date of Electronic Publication: 2015 Nov 20.

Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.

Autor: Van Laere K; Division of Nuclear Medicine, K.U. Leuven and University Hospital Leuven, Leuven, Belgium. koen.vanlaere@uzleuven.be, De Hoon J, Bormans G, Koole M, Derdelinckx I, De Lepeleire I, Declercq R, Sanabria Bohorquez SM, Hamill T, Mozley PD, Tatosian D, Xie W, Liu Y, Liu F, Zappacosta P, Mahon C, Butterfield KL, Rosen LB, Murphy MG, Hargreaves RJ, Wagner JA, Shadle CR

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2012 Aug; Vol. 92 (2), pp. 243-50. Date of Electronic Publication: 2012 Jun 27.